Reven Pharmaceuticals

Reven Pharmaceuticals develops proprietary pharmacological solutions targeting immune system homeostasis. Its lead asset, Rejuveinix (RJX), an intravenous formulation with antioxidant and anti-inflammatory properties, has completed early-phase clinical trials in sepsis and COVID-related acute lung/liver injury. The company reports successful completion of part one of a Phase II trial in high-risk COVID patients and continues to advance RJX across several indications including cardiovascular disease and oncology. Additional programs are at preclinical or IND-enabling stages targeting wound healing, CNS disorders, autoimmune diseases, ocular conditions, and more.